EuBiologics Co., Ltd. (KOSDAQ:206650)

Market Cap	405.60B
Revenue (ttm)	96.04B
Net Income (ttm)	24.87B
Shares Out	36.67M
EPS (ttm)	n/a
PE Ratio	16.31
Forward PE	8.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	147,063
Average Volume	145,604
Open	11,240
Previous Close	11,150
Day's Range	10,940 - 11,240
52-Week Range	10,000 - 14,950
Beta	0.33
RSI	31.75
Earnings Date	Feb 2, 2026

About EuBiologics

EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen presenting cell expressing TLR 4 agonist, stimulating the production of cytokines and co-stimulatory molecules. In addition, it offers carrier protein ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 206650